ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells-Reference-Cited by-同舟云学术

ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells

Published:2020-09-21 Issue:11 Volume:16 Page:1208-1217
ISSN:1552-4450
Container-title:Nature Chemical Biology
language:en
Short-container-title:Nat Chem Biol

Author:

Yamamoto Junichi,Suwa Tetsufumi,Murase Yuki,Tateno Shumpei,Mizutome Hirotaka,Asatsuma-Okumura Tomoko^ORCID,Shimizu Nobuyuki,Kishi Tsutomu,Momose Shuji,Kizaki Masahiro,Ito Takumi^ORCID,Yamaguchi Yuki,Handa Hiroshi^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

https://www.nature.com/articles/s41589-020-0645-3.pdf

Reference42 articles.

1. Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345–1350 (2010).

2. Zhu, Y. X. et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118, 4771–4780 (2011).

3. Lopez-Girona, A. et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26, 2326–2335 (2012).

4. Chamberlain, P. et al. Structure of the human cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat. Struct. Mol. Biol. 21, 803–809 (2014).

5. Fischer, E. et al. Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512, 49–53 (2014).

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pomalidomide sensitizes lung cancer cells to TRAIL/CDDP-induced apoptosis via directly targeting electron transfer flavoprotein alpha subunit;Bioorganic Chemistry;2024-12

2. Coupling proximity biotinylation with genomic targeting to characterize locus-specific changes in chromatin environments;2024-07-26

3. Revealing the clinical impact of MTOR and ARID2 gene mutations on MALT lymphoma of the alimentary canal using targeted sequencing;Diagnostic Pathology;2024-07-25

4. IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma;Cancer Cell;2024-07

5. Targeting the ubiquitin pathway in lymphoid malignancies;Cancer Letters;2024-07